Effect of continuation treatment on health-related quality of life in remitted psychotic depression.
Ryma A Bendel, George S Alexopoulos, Patricia Marino et al.
✦ AI-curated · Sources linked
In 30 seconds
This randomized controlled trial investigated the impact of continuation treatment with sertraline plus olanzapine on health-related quality of life (HRQOL) in 126 individuals aged 18 to 85 with remitted psychotic depression. Results indicated that sertraline plus olanzapine led to better outcomes in the Role Emotional and Mental Health domains compared to sertraline plus placebo, with significant declines in these scores associated with relapse.
Key findings
- Sertraline plus olanzapine improved Role Emotional and Mental Health scores compared to sertraline plus placebo.
- Approximately one quarter of participants in the placebo group had RE and MH scores more than two standard deviations below the population mean.
- Relapse was linked to a marked decline in Role Emotional and Mental Health scores.
Why it matters
Understanding the relationship between pharmacotherapy and HRQOL in remitted psychotic depression can guide treatment decisions, emphasizing the importance of preventing relapse to maintain mental health and overall quality of life.